Q-omics provides the consensus-scored MIR301A profile across patient tissues and cancer cell-line models. MIR301A expression is associated with patient survival in 9 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, MIR301A is differentially expressed in 1, with the highest sampling consensus in STAD. Additionally, MIR301A RNA expression shows 8,198 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight BLCA, STAD, and LSCC as cancer lineages where MIR301A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR301A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR301A survival associations across molecular data types. MIR301A RNA expression shows survival associations in the most cancer types (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR301A RNA expression–survival associations across cancer types. High MIR301A expression shows unfavorable associations in BLCA, UCS, MESO, HNSC and UCEC, but favorable associations in ESCA. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for MIR301A RNA expression.
This table summarizes MIR301A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in STAD for RNA.
This table ranks reproducible tumor–normal expression differences for MIR301A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR301A shows higher tumor expression in STAD. The STAD box plot shows higher MIR301A RNA expression in tumor versus normal tissue (log2 FC = +0.182, t-test p = .046).
This table shows molecular features associated with MIR301A in patient tissues and cancer cell lines. In patient samples, MIR301A shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
